| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99199 |
Unlisted special service, procedure or report |
110,609 |
56,920 |
$894K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,299 |
6,769 |
$730K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,713 |
4,453 |
$345K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,705 |
3,058 |
$321K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
3,112 |
2,636 |
$271K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,109 |
2,379 |
$246K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
5,757 |
4,702 |
$195K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
9,747 |
8,006 |
$175K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,703 |
1,427 |
$164K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
8,110 |
6,119 |
$65K |
| D0145 |
Oral evaluation for a patient under three years of age |
1,949 |
1,584 |
$62K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,497 |
1,169 |
$53K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,038 |
825 |
$49K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,766 |
1,221 |
$42K |
| 96127 |
|
7,273 |
5,332 |
$29K |
| D1206 |
Topical application of fluoride varnish |
1,676 |
1,425 |
$24K |
| 99381 |
|
269 |
194 |
$22K |
| 90474 |
|
1,249 |
982 |
$22K |
| 99215 |
Prolong outpt/office vis |
164 |
141 |
$20K |
| 83718 |
|
1,721 |
1,367 |
$14K |
| 99383 |
|
138 |
121 |
$13K |
| 90651 |
|
1,021 |
847 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
922 |
817 |
$12K |
| 99408 |
|
525 |
411 |
$10K |
| 82465 |
|
1,995 |
1,575 |
$9K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
200 |
187 |
$7K |
| 96161 |
|
2,007 |
1,514 |
$6K |
| 85018 |
|
3,312 |
2,686 |
$5K |
| 0001A |
|
73 |
47 |
$3K |
| 99382 |
|
35 |
28 |
$3K |
| 0071A |
|
59 |
48 |
$3K |
| 90734 |
|
310 |
259 |
$3K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
180 |
158 |
$3K |
| 87807 |
|
227 |
205 |
$3K |
| 92552 |
|
7,638 |
6,371 |
$2K |
| 96160 |
|
545 |
455 |
$1K |
| 0072A |
|
27 |
17 |
$1K |
| 90686 |
|
2,687 |
2,303 |
$1K |
| 0002A |
|
52 |
23 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
12 |
12 |
$970.32 |
| 99173 |
|
8,039 |
6,709 |
$615.09 |
| 90715 |
|
220 |
190 |
$445.21 |
| 94664 |
|
42 |
39 |
$445.20 |
| 94760 |
|
2,268 |
1,444 |
$420.23 |
| 90633 |
|
1,603 |
1,340 |
$340.27 |
| 90619 |
|
319 |
255 |
$304.57 |
| 99401 |
|
18 |
13 |
$298.78 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
29 |
23 |
$295.22 |
| 90698 |
|
1,904 |
1,493 |
$220.46 |
| 90710 |
|
288 |
259 |
$205.39 |
| 90621 |
|
30 |
26 |
$161.30 |
| 81003 |
|
28 |
24 |
$66.84 |
| 90744 |
|
1,189 |
933 |
$26.09 |
| 36416 |
|
1,106 |
956 |
$3.37 |
| 90670 |
|
2,354 |
1,847 |
$0.00 |
| 90700 |
|
177 |
164 |
$0.00 |
| 90685 |
|
69 |
59 |
$0.00 |
| 90648 |
|
162 |
132 |
$0.00 |
| 90707 |
|
190 |
156 |
$0.00 |
| 91300 |
|
209 |
110 |
$0.00 |
| 90713 |
|
13 |
13 |
$0.00 |
| J7645 |
Ipratropium bromide, inhalation solution, compounded product, administered through dme, unit dose form, per milligram |
15 |
13 |
$0.00 |
| 99000 |
|
2,388 |
1,842 |
$0.00 |
| 90680 |
|
1,331 |
1,027 |
$0.00 |
| 90696 |
|
258 |
235 |
$0.00 |
| 90697 |
|
51 |
51 |
$0.00 |
| 90716 |
|
187 |
154 |
$0.00 |
| 90677 |
|
262 |
253 |
$0.00 |
| 91307 |
|
121 |
81 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
41 |
35 |
$0.00 |
| 94761 |
|
29 |
23 |
$0.00 |
| 90656 |
|
180 |
169 |
$0.00 |
| 90723 |
|
16 |
12 |
$0.00 |